Drug shortage
Rifampin Injection · Mylan Institutional, a Viatris Company
FDA drug shortage · Current · updated Oct 5, 2026
Key facts
| Generic name | Rifampin Injection |
|---|---|
| Company | Mylan Institutional, a Viatris Company |
| Presentation | Rifampin, Injection, 600 mg (NDC 67457-445-60) |
| Dosage form | Injection |
| Status | Current |
| Reason for shortage | Demand increase for the drug |
| Therapeutic category | Anti-Infective |
| Package NDCs | 67457-445-60 |
| First posted | Feb 17, 2021 |
| Last updated | Oct 5, 2026 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: